BCM
ALXN

Boltwood Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Boltwood Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,975
Closed -$455K – 151
2021
Q1 		$455K Sell
2,975
-195
-6% -$30.2K 0.2% 108
2020
Q4 		$495K Sell
3,170
-160
-5% -$20.6K 0.24% 100
2020
Q3 		$381K Buy
3,330
+5
+0.2% +$539 0.21% 106
2020
Q2 		$373K Hold
3,325
– – 0.23% 100
2020
Q1 		$299K Buy
3,325
+955
+40% +$93.7K 0.21% 111
2019
Q4 		$256K Sell
2,370
-4,900
-67% -$524K 0.14% 130
2019
Q3 		$712K Buy
7,270
+240
+3% +$27.1K 0.45% 77
2019
Q2 		$921K Buy
+7,030
New +$906K 0.59% 57

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Boltwood Capital Management's ALXN Position: Q2 2021 in Review

Boltwood Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 2,975 shares — an estimated $455K sold.

Boltwood Capital Management first reported a position in ALXN in Q2 2019 and held it in 8 quarters. The position peaked at $921K in Q2 2019. 707 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Boltwood Capital Management reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Boltwood Capital Management sold 2,975 Alexion Pharmaceuticals shares in Q2 2021, an estimated $455K.
  • Boltwood Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2019 and held it in 8 quarters.
  • Boltwood Capital Management's Alexion Pharmaceuticals position peaked at $921K in Q2 2019.
  • 707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Boltwood Capital Management's 13F filing for Q2 2021, filed 6 Jul 2021.